These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 18029940)

  • 1. FDA approves new breast cancer treatment.
    Thompson CA
    Am J Health Syst Pharm; 2007 Dec; 64(23):2406. PubMed ID: 18029940
    [No Abstract]   [Full Text] [Related]  

  • 2. Approved agents for metastatic breast cancer.
    Fornier MN
    Semin Oncol; 2011 Jun; 38 Suppl 2():S3-10. PubMed ID: 21600382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ixabepilone (Ixempra) for breast cancer.
    Med Lett Drugs Ther; 2008 Jan; 50(1278):7-8. PubMed ID: 18219261
    [No Abstract]   [Full Text] [Related]  

  • 4. Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms.
    Vahdat L
    Oncologist; 2008 Mar; 13(3):214-21. PubMed ID: 18378531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ixabepilone: new drug. Similar to taxanes, but no better.
    Prescrire Int; 2009 Aug; 18(102):160. PubMed ID: 19743574
    [No Abstract]   [Full Text] [Related]  

  • 6. Ixabepilone for the treatment of breast cancer.
    Alvarez RH; Valero V; Hortobagyi GN
    Ann Med; 2011; 43(6):477-86. PubMed ID: 21585248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer.
    Egerton N
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1005-12. PubMed ID: 20886213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of epothilones in breast cancer therapy.
    Cianfrocca M
    Curr Opin Oncol; 2008 Nov; 20(6):634-8. PubMed ID: 18841044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes.
    Yardley DA
    Clin Breast Cancer; 2008 Dec; 8(6):487-92. PubMed ID: 19073502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer.
    Boehnke Michaud L
    J Oncol Pharm Pract; 2009 Jun; 15(2):95-106. PubMed ID: 19171553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged disease control in a patient with anthracycline- and taxane-resistant breast cancer.
    Castaneda CA; Gómez HL
    Clin Breast Cancer; 2009 Nov; 9(4):E1-3. PubMed ID: 19933071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ixabepilone plus capecitabine for breast cancer patients with an early metastatic relapse after adjuvant chemotherapy: two clinical trials.
    Fornier M
    Clin Breast Cancer; 2010 Oct; 10(5):352-8. PubMed ID: 20920979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes.
    Hortobagyi GN; Gomez HL; Li RK; Chung HC; Fein LE; Chan VF; Jassem J; Lerzo GL; Pivot XB; Hurtado de Mendoza F; Xu B; Vahdat LT; Peck RA; Mukhopadhyay P; Roché HH
    Breast Cancer Res Treat; 2010 Jul; 122(2):409-18. PubMed ID: 20454927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epothilones: clinical update and future directions.
    Donovan D; Vahdat LT
    Oncology (Williston Park); 2008 Apr; 22(4):408-16; discussion 416, 421, 424 passim. PubMed ID: 18472615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Budget impact analysis of ixabepilone used according to FDA approved labeling in treatment-resistant metastatic breast cancer.
    Ho J; Zhang L; Todorova L; Whillans F; Corey-Lisle P; Yuan Y
    J Manag Care Pharm; 2009; 15(6):467-75. PubMed ID: 19610679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical studies with epothilones for the treatment of metastatic breast cancer.
    Vahdat LT
    Semin Oncol; 2008 Apr; 35(2 Suppl 2):S22-30; quiz S40. PubMed ID: 18410796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current combination chemotherapy regimens for metastatic breast cancer.
    Schwartz J
    Am J Health Syst Pharm; 2009 Dec; 66(23 Suppl 6):S3-8. PubMed ID: 19923317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ixabepilone, a new treatment option for metastatic breast cancer.
    Toppmeyer DL; Goodin S
    Am J Clin Oncol; 2010 Oct; 33(5):516-21. PubMed ID: 20023567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epothilones in breast cancer: current status and future directions.
    Atzori F; Fornier M
    Expert Rev Anticancer Ther; 2008 Aug; 8(8):1299-311. PubMed ID: 18699766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful rechallenge after ixabepilone-induced radiation recall dermatitis using an alternative dosing strategy.
    Ford JN; Newton M; Jordan C; Abraham J
    J Oncol Pharm Pract; 2013 Mar; 19(1):89-92. PubMed ID: 22323422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.